Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10907241 | 0.85 | TSHR (0.39) | TSHRCA9CA2CA12RAB9A | |
| SCHEMBL824596 | 0.78 | CRBN (0.62) | TSHRALDH1A1TDP1 | |
| SCHEMBL845434 | 0.77 | CRBN (0.57) | TSHRALDH1A1TDP1KDM4E | |
| SCHEMBL10000098 | 0.76 | TSHR (0.53) | TSHRCA9CA2ELANECA12 | |
| SCHEMBL27009830 | 0.75 | POLB (0.42) | NPC1ALDH1A1CYP2C19TDP1KDM4E | |
| SCHEMBL6896499 | 0.74 | TSHR (0.57) | TSHRCA9CA2ELANECA12 | |
| SCHEMBL11305121 | 0.74 | TSHR (0.54) | TSHRCA9CA2ELANECA12 | |
| SCHEMBL3125601 | 0.73 | CRBN (0.55) | TSHRALDH1A1TDP1KDM4E | |
| SCHEMBL6903492 | 0.73 | TSHR (0.56) | TSHRCA9CA2ELANECA12 | |
| SCHEMBL18263933 | 0.73 | CRBN (0.55) | TSHRALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-5593990-A | Methods and compositions for inhibition of angiogenesis | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0688211-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020085-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0110219-B1 | HETEROCYCLIC SUBSTITUTED NITRILES, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BASF Aktiengesellschaft (DE) | 1986-06-11 | — | — | EP | disclosed |
| US-4563474-A | PSYCHOLOGICAL DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0110219-A1 | Heterocyclic substituted nitriles, their production and their use as medicaments | BASF Aktiengesellschaft (DE) | 1984-06-13 | — | — | EP | disclosed |